Novartis Retreats, But Not Entirely, on 340B Contract Pharmacy (Update 2)
Update 2, Friday Oct. 30, 4:00 p.m. EDT—Hospital group 340B Health said Novartis’ action was inexcusable. “The 340B statute is crystal clear,” 340B Health President and CEO Maureen Testoni said. Drug companies cannot “put limits on [340B] discounts based on where hospitals are distributing the drugs to their patients. Manufacturers that knowingly and intentionally overcharge for their drugs are subject to civil monetary penalties. It is long past time for the Department of Health & Human Services to put a stop to this unlawful behavior.”
×